Clinical Trials Using Hydroxyurea
Clinical trials are research studies that involve people. The clinical trials on this list are studying Hydroxyurea. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
PEG-Interferon Alfa-2a or Hydroxyurea in Treating Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia
This research looks at two conditions, essential thrombocythemia (ET) and polycythemia vera (PV). ET causes people to produce too many blood cells called platelets and PV causes too many platelets and red blood cells to be made. The purpose of this study is to look at the effectiveness of giving participants who have been diagnosed with ET or PV one of two different study regimens over time. The study regimens are either “PEGASYS” (or pegylated interferon alfa-2a [PEG interferon alfa-2a]) or “aspirin and hydroxyurea” (also called hydroxycarbamide). Patients may be a newly diagnosed subject or a subject already receiving treatment for either PV or ET. Each of the study drugs used in this study is already being used to treat subjects with ET or PV currently but we are unsure which study drug is better.
Location: 15 locations
Mesenchymal Stem Cell Transplant in Promoting Stem Cell Engraftment in Patients with Severe Sickle Cell Disease Undergoing Donor Blood Stem Cell Transplant
This phase I clinical trial studies the side effects and best dose of mesenchymal stem (stromal) cells in promoting stem cell engraftment in patients with severe sickle cell disease who are undergoing a donor blood stem cell transplant. Mesenchymal stem cells obtained from the patient and grown outside the body in a laboratory may have a lower chance of being rejected, and may promote tolerance, helping the donor’s immune cells accept the recipient’s body.
Location: Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia
Nab-Paclitaxel and Carboplatin Followed by Chemoradiation in Treating Patients with Recurrent Head and Neck Cancer
This phase I trial studies the side effects and best dose of nab-paclitaxel when given together with carboplatin followed by chemoradiation in treating patients with head and neck cancer that has come back (recurrent). Drugs used in chemotherapy, such as nab-paclitaxel, carboplatin, fluorouracil, and hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving nab-paclitaxel followed by chemoradiation therapy may be a better treatment for head and neck cancer.
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
This partially randomized phase I / II trial studies the side effects and best dose of veliparib when given together with combination chemotherapy and to see how well they work in treating patients with stage IV head and neck cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective when given with or without veliparib in treating head and neck cancer.
Location: 5 locations